Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See
full details
.
I Agree
×
Join today and have your say! It’s FREE!
Join Now
Sign In
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.
Join Today
or
Sign in with existing account
Privacy Policy
|
Disclaimer
Sign In
Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Remember me
Forgot Password?
Sign In
or
Sign Up
Privacy Policy
|
Disclaimer
Please Try Again
{{ error }}
Send my password
Submit
Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Linking with Facebook:
Stockhouse membership requires an email address which must be shared by Facebook.
By default, joining or signing in using your Facebook account will work and the email address will be shared by Facebook automatically.
If you change your Facebook permissions to restrict Stockhouse from receiving your email while joining or signing in to Stockhouse then it will fail.
Please do not modify the permission settings during sign-in.
Sign in with Facebook
Return to Signup Options
Home
Community
Bullboards
Blogs
Groups
Messages
Markets
Stocks
TSX
TSXV
CSE
NASDAQ
NYSE
NYSE American
Cryptocurrency
Currencies
Market Movers
News
Featured News
Trending News
Canadian Press Releases
US Press Releases
Video
Editorial
Thematic Insights
Independent Reports
Interviews
Buzz on the Bullboards
Portfolio
Watchlist
Portfolio
Showcase Companies
DealRoom
Quote
|
Bullboard
|
News
|
Opinion
|
Profile
|
Peers
|
Filings
|
Financials
|
Price History
|
Ratios
|
Insiders
Bullboard - Stock Discussion Forum
Innovation Pharmaceuticals Inc (EM)
IPIX
Healthcare
Biotechnology
Innovation Pharmaceuticals Inc., a clinical stage biopharmaceutical company, develops small molecule therapies to treat inflammatory diseases, cancer, dermatology, and anti- infective. Its lead drug candidate is Brilacidin, a therapeutic for the treatment of oral mucositis, inflammatory bowel disease, acute bacterial skin and skin structure infection, and COVID-19. The company has a license...
agreement with Alfasigma S.p.A.; and collaborative research agreement with Fox Chase Chemical Diversity Center, Inc. The company was formerly known as Cellceutix Corporation and changed its name to Innovation Pharmaceuticals Inc. in June 2017. Innovation Pharmaceuticals Inc. was incorporated in 2005 and is headquartered in Wakefield, Massachusetts.
see more
Join the community and start posting on the bullboards today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Add To Watchlist
Create a portfolio watchlist today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Bullboard (EXPM:IPIX)
New Post
View:
Posts & Comments
Threaded Posts
Prev
1
2
3
4
5
Next
(0)
•••
Brito1
X
Post by
Brito1
on Nov 23, 2018 1:55pm
Ageement soon?
Dear IPIX Shareholders, In just a few short weeks, we will be convening our Brilacidin-Oral Mucositis End-of-Phase 2 regulatory meeting. Success here not only would help us to complete development of
...more
(0)
•••
Brito1
X
Comment by
Brito1
on Sep 24, 2018 12:57pm
RE:Connect the dots
(0)
•••
Brito1
X
Post by
Brito1
on Sep 24, 2018 12:55pm
Connect the dots
<brbased on="" these="" consistent="" and="" compelling="" trial="" results="" across="" multiple=""
...more
(0)
•••
aragon1959
X
Comment by
aragon1959
on Sep 16, 2018 9:50am
RE:BTD request Likely received by FDA, but when?
agree with you Brito 10K was a bit confusing but I still have a good feeling that we longs will do very well in IPIX My predictions and IMO only : BDT for B-OM will come first and soon , maybe even
...more
(0)
•••
Brito1
X
Post by
Brito1
on Sep 14, 2018 3:48pm
BTD request Likely received by FDA, but when?
Ideally, a Breakthrough Therapy designation request should be received by FDA no later than the end-of-phase-2 meetings if any of the features of the designation are to be obtained. FDA will respond
...more
(0)
•••
aragon1959
X
Comment by
aragon1959
on Aug 23, 2018 4:45pm
RE:All drugs taken...
Thx Brito excellent points. I think K was put in backburner for a now, while IPIX concetrates on B and P. my winning horse is definetly B but P has great potentials as well. very exciting times for
...more
(0)
•••
Brito1
X
Post by
Brito1
on Aug 23, 2018 4:06pm
All drugs taken...
..Orally. Such drug product packaging in the form of sachets provides patients with a convenient, portable, quick-mixing instant Brilacidin oral rinse therapy. Prurisol, an oral psoriasis drug
...more
(0)
•••
Brito1
X
Comment by
Brito1
on Aug 22, 2018 2:47pm
RE:RE:Looks to me
Looking for partnership not acquisition at this time as I believe we would be severely short changed.
(0)
•••
aragon1959
X
Comment by
aragon1959
on Aug 22, 2018 6:55am
RE:Looks to me
agree with you Brito I wouldnt be surprise ,if with BTD comes offer /partnership / acquisition by BP Its 2-4 Bln $ / year market and growing GLTA
(0)
•••
Brito1
X
Post by
Brito1
on Aug 21, 2018 6:49pm
Looks to me
that the next news release will be yay or nay to Breakthrough Therapy Designation. if IPIX concluded data Analysis of it's phase 2 clinical trial May 9th and submitted for the Designation sometime
...more
(0)
•••
Brito1
X
Post by
Brito1
on Aug 20, 2018 7:10pm
Short timeline...
Ideally, a Breakthrough Therapy designation request should be received by FDA no later than the end-of-phase-2 meetings if any of the features of the designation are to be obtained. FDA will respond
...more
(0)
•••
aragon1959
X
Comment by
aragon1959
on Jul 05, 2018 6:47am
RE:RE:News - Achieving Milestones
...and I truly expect BP news first followed by P data and than B FDA approval I may be wrong in regards to chronology of events but BP partnership would be huge and positive event with SP reaching 5
...more
(0)
•••
aragon1959
X
Comment by
aragon1959
on Jul 05, 2018 6:41am
RE:News - Achieving Milestones
Thanks Brito I think next 3 month will be absolutely crucial in IPIX history and if they will meet at least two of three milestones we longs will be a winners in a huge way B and P market value is
...more
(0)
•••
Brito1
X
Post by
Brito1
on Jun 28, 2018 7:02pm
News - Achieving Milestones
$1 million upon announcement of Breakthrough Therapy Designation from the FDA for Brilacidin as a potential treatment for oral mucositis (OM). $2 million upon announcement of results from the recently
...more
(1)
•••
kaos12
X
Post by
kaos12
on Jun 05, 2018 9:19am
Article on various companies working on OM
https://www.baystreet.ca/articles/stockstowatch/38594/Taking-a-Page-from-Mercks-Gardasil-and-Glaxos-Requip-These-Small-Companies-Look-to-Cement-Riches-for-Shareholders-in-New-Category-of-Oral
...more
Prev
1
2
3
4
5
Next
Thank You
Your Report has been submitted.
Report Abusive Content
×
Close
Sign up to get access
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Market Update
{{currentVideo.title}}
{{currentVideo.relativeTime}}
{{previousButtonTitle}}
{{nextButtonTitle}}
A daily snapshot of everything
from market open to close.
Podcasts